Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease-Reference-Cited by-同舟云学术

Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease

Published:2018-01-25 Issue: Volume:12 Page:
ISSN:1662-453X
Container-title:Frontiers in Neuroscience
language:
Short-container-title:Front. Neurosci.

Author:

Plank Anne-Christine,Canneva Fabio,Raber Kerstin A.,Urbach Yvonne K.,Dobner Julia,Puchades Maja,Bjaalie Jan G.,Gillmann Clarissa,Bäuerle Tobias,Riess Olaf,Nguyen Hoa H. P.,von Hörsten Stephan

Publisher

Frontiers Media SA

Subject

General Neuroscience

Reference41 articles.

1. Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease;Abada;PLoS ONE,2013

2. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation;Bauer;J. Neurochem.,2005

3. Obsessive and compulsive symptoms in prediagnosed Huntington's disease;Beglinger;J. Clin. Psychiatry,2008

4. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males;Bode;Hum. Mol. Genet.,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of CNS and extra-CNS infections to neurodegeneration: a narrative review;Journal of Neuroinflammation;2024-06-06

2. Young human alpha synuclein transgenic (BAC-SNCA) mice display sex- and gene-dose-dependent phenotypic disturbances;Behavioural Brain Research;2024-03

3. Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease;Frontiers in Neuroscience;2024-02-07

4. Investigating cell therapies in animal models of Parkinson's and Huntington's disease: Current challenges and considerations;International Review of Neurobiology;2022

5. Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons;International Review of Neurobiology;2022